BioRestorative Therapies (FRA:9OF) Tariff Resilience Score: 7/10 (As of Jul. 03, 2026)


FRA:9OF BioRestorative Therapies Inc FRA:9OF
51 GF Score
Price €0.34
GF Value €1.28
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies Tariff Resilience Score?

BioRestorative Therapies FRA:9OF +4.97% 51 Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus rates FRA:9OF with a GF Score™ of 51/100 and a GF Value™ of €1.28 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,373 Biotechnology companies, BioRestorative Therapies ranks better than 90.39% on this metric.

BioRestorative Therapies has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

BioRestorative Therapies has BioRestorative Therapies Inc has moderate exposure due to its niche market and reliance on specific biotech components. It has some pricing power and can source alternatives, but its international sales are limited, reducing overall tariff impact.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BioRestorative Therapies might have Highly Resilient.

BioRestorative Therapies  (FRA:9OF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BioRestorative Therapies Tariff Resilience Score Related Terms

FRA:9OF vs CVKD, JSPR, APRE: Tariff Resilience Score Comparison

For the Biotechnology subindustry, BioRestorative Therapies's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Tariff Resilience Score falls into.


FRA:9OF
51GF Score
BioRestorative Therapies Inc FRA:9OF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
BioRestorative Therapies (FRA:9OF) has a Tariff Resilience Score of 7 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BioRestorative Therapies ranks #132 out of 1373 companies in the Biotechnology industry, placing it in the top 9.6%.
Is BioRestorative Therapies' Tariff Resilience Score too high?
BioRestorative Therapies' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. BioRestorative Therapies' value of 7 is 75% above this industry median. Based on the distribution chart, BioRestorative Therapies ranks #132 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Tariff Resilience Score compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #132 out of 1373 companies for Tariff Resilience Score. This places BioRestorative Therapies in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. BioRestorative Therapies' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.28, compared to a current price of €0.34 — trading 73.6% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of €0.34 is trading 73.6% below its estimated GF Value™ of €1.28. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for FRA:9OF:

  • Tariff Resilience Score: 7
  • GF Value™: €1.28 vs. price of €0.34 (73.6% below fair value)
  • GF Score™: 51/100 with 3 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1373)

No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioRestorative Therapies Business Description

Other Exchanges BRTX:USA
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score

Get the complete analysis for FRA:9OF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price
€1.28
GF Value